Abstract: This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.

Abstract: It is an object of the present invention to provide methods for assessing the efficacy of a remote ischemic preconditioning procedure though the measurement of urinary TIMP-2 and IGFBP7 concentrations.

Abstract: The present invention provides a compound with a general formula (I) or a salt thereof, wherein, R1 and R2, are, independently of each other, F or CnF2n+1 with n=1-10, and R3 and R4 are, independently of each other, C1-C10-alkyl.

Abstract: The present invention relates to a process for the enzymatic production of a dipeptide composition from a cyanophycin (CGP) or CGP-like polymer preparation by degrading the polymer preparation with an CGPase, a CGPase particularly adapted for said process, and the use of cyanophycin (CGP) or CGP-like polymers or fragments thereof, notably a dipeptide composition obtained by the process as defined above, as pharmaceutical composition, medicament, or as food or feed substitute.

Abstract: The invention relates to lithium 1-trifluoromethoxy-1,2,2,2-tetra-fluoroethanesulphonate, the use of lithium 1-trifluoromethoxy-1,2,2,2-tetra-fluoroethanesulphonate as electrolyte salt in lithium-based energy stores and also ionic liquids comprising 1-trifluoro-methoxy-1,2,2,2-tetrafluoro-ethanesulphonate as anion.

Abstract: The present invention is directed to a method for diagnosing inflammatory diseases based on the marker CALGRANULIN C, particularly for diagnosing specific stages of inflammatory diseases and/or for determining the risk of relapse and/or for discriminating between diseases with similar symptoms, said method comprising the steps of (a) obtaining a biological sample of mammalian body fluid or tissue to be diagnosed; (b) determining the amount and/or concentration of CALGRANULIN C polypeptide and/or nucleic acids encoding the polypeptide present in said biological sample; and (c) comparing the amount and/or concentration of CALGRANULIN C polypeptide determine in said biological sample with the amount and/or concentration of CALGRANULIN C polypeptide as determined in a control sample and/or comparing the amount and/or concentration of nucleic acids encoding CALGRANULIN C polypeptide determined in said biological sample with the amount and/or concentration of nucleic acids encoding CALGRANULIN C polypeptides measur

Abstract: The invention provides a combination of an isolated peptide or peptidomimetic that includes the sequence of SEQ ID NO: 1 or a homolog thereof, and an isolated peptide or peptidomimetic that includes the sequence of SEQ ID NO: 2. The invention also provides a method of treating a BCR-ABL associated disease or a c-ABL associated disease in a subject. The method is based on the use of the aforementioned combination of one or more isolated peptides or peptidomimetics.

Abstract: The invention relates to the use of lithium-2-pentafluoroethoxy-1,1,2,2-tetrafluoro-ethanesulfonate as a conductive salt in lithium-based energy stores and to electrolytes containing lithium-2-pentafluoroethoxy-1,1,2,2-tetrafluoro-ethanesulfonate.

Abstract: The invention relates to a method for producing carbon-coated, transition metal-doped zinc oxide particles and the use thereof as electrode material for alkali metal ion batteries and, in particular, lithium ion batteries.

Abstract: The present invention relates to an isolated polypeptide comprising at least one intein or at least one intein fragment of said intein, wherein said intein is a naturally split intein with a N-terminal intein fragment split after 14-60 amino acids from the intein's N-terminal end and methods of using the same.

Abstract: Provided is an isolated peptide or a peptidomimetic comprising a sequence corresponding to amino acid positions 431-616 or 411-616 of the human protein TLR4 or corresponding to amino acid positions 84-131 of the human protein MD-2. Provided is also an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 411 to 616 of variant 1 the human protein TLR4. Provided is further an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 86 to 131 of the human protein MD2. Provided is further the use of such antibody in the treatment or diagnosis of an inflammatory disorder. Also provided is an in-vitro method of identifying a compound capable of inhibiting the formation of a complex between one of the above peptides or whole molecules and an S100A8 or S100A9 or S100A8/S100A9 protein or a functional fragment thereof.

Abstract: An apparatus for mass spectrometry includes a laser ablation sampler comprising a laser ablation chamber and a laser which produces a laser beam. The laser irradiates and ablates a material from a sample placed within the laser ablation chamber so as to generate an ablated sample material. A transfer tube system comprising transfer tubes connect the laser ablation sample with, and provides a parallel and simultaneous transport of the ablated sample material to, each of a soft and a hard ionization source. The soft and hard ionization sources interact with the ablated sample material to respectively generate ion populations having a mass-to-charge ratio distribution. These respective mass-to-charge ratio distributions are respectively transmitted to a molecular mass spectrometer and to an elemental mass spectrometer which provide information on the mass-to-charge ratio distribution. The mass-to-charge ratio distributions are used to characterize a composition of the ablated sample material.

Abstract: The present invention relates to a method and a device for providing a current of spin-polarized electrons. More particularly, the present invention is suited for use in spin electronics or detection of spin-polarized electrons.

Abstract: The present invention relates to novel compounds of formulae (I) and (II) which are useful in the prevention, treatment and diagnosis, in vivo diagnosis of diseases or disorders related to S1P receptors, in particular, in diseases which are connected to the regulatory function of sphingosine-1-phosphate (S1P) and its analogs, such as inflammation, pain, autoimmune diseases and cardiovascular diseases.

Abstract: The present invention relates to the use of Yersinia outer protein M (YopM)in the prevention and/or treatment of psoriasis by cutaneous, intradermalor subcutaneous administration. In particular, the present invention relates to the use of YopM in the treatment of plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, arthritis psoriasis.

Abstract: The present invention is related to the tripeptide (I)Lys-(d)Pro-(I)Thr (KdPT) or pharmaceutically acceptable salts thereof for therapeutic, prophylactic therapeutic or cosmetic treatment of a disease with increased apoptosis, wherein the treatment has an anti-apoptotic effect. The present invention is also related to the use of KdPT or pharmaceutically acceptable salts thereof for the manufacture of a pharmaceutical or cosmetic composition for an anti-apoptotic treatment of disorders that are related with increased apoptosis.

Abstract: The present invention relates to a process for the enzymatic production of a dipeptide composition from a cyanophycin (CGP) or CGP-like polymer preparation by degrading the polymer preparation with an CGPase, a CGPase particularly adapted for said process, and the use of cyanophycin (CGP) or CGP-like polymers or fragments thereof, notably a dipeptide composition obtained by the process as defined above, as pharmaceutical composition, medicament, or as food or feed substitute.

Abstract: The invention is about E. coli host cells which are capable to convert glycerol to serinol. Furthermore, a process for producing serinol is disclosed, which comprises culturing E. coli host cells inactive for triosephosphate isomerase and active for dihydroxyacetone phosphate aminotransferase to convert glycerol to serinol, induction of conversion from glycerol to serinol by adding at least glycerol to the cell culture, and isolating serinol from the cell culture.

Abstract: The invention provides a combination of an isolated peptide or peptidomimetic that includes the sequence of SEQ ID NO: 1 or a homolog thereof, and an isolated peptide or peptidomimetic that includes the sequence of SEQ ID NO: 2. The invention also provides a method of treating a BCR-ABL associated disease or a c-ABL associated disease in a subject. The method is based on the use of the aforementioned combination of one or more isolated peptides or peptidomimetics.

Abstract: The present invention provides a compound with a general formula (I) or a salt thereof, wherein, R1 and R2, are, independently of each other, F or CnF2n+1 with n=1-10, and R3 and R4 are, independently of each other, C1-C10-alkyl.